The production and characteristics of solid lipid nanoparticles (SLNs)

Biomaterials

Volumn 24, Issue 10, 2003, Pages 1781-1785

  Hou, DongZhi ^a   Xie, ChangSheng ^a   Huang, KaiJin ^a   Zhu, ChangHong ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Entrapment efficiency; Laser diffractometry; Modified high shear homogenization and ultrasound techniques; Solid lipid nanoparticles

Indexed keywords

DIFFERENTIAL SCANNING CALORIMETRY; LIPIDS; PARTICLE SIZE ANALYSIS; X RAY DIFFRACTION;

LASER DIFFRACTOMETRY (LD); SOLID LIPID NANOPARTICLES (SLN);

NANOSTRUCTURED MATERIALS;

DRUG CARRIER; MIFEPRISTONE; SOLID LIPID NANOPARTICLE;

ARTICLE; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STABILITY; LASER DIFFRACTION; LIPOPHILICITY; MODEL; PARTICLE SIZE; PRIORITY JOURNAL; ULTRASOUND; X RAY DIFFRACTION;

EID: 0037404980     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0142-9612(02)00578-1     Document Type: Article

References (25)

1. Muller R.H., Karsten M., Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state or the art. Eur J Pharm Biopharm. 50:2000;161-177.
2. De Vringer. Topical preparation containing a suspension of solid lipid particles. US Patent No. 5904932, 1999.
3. Westesen K. Particles with modified physico-chemical properties, their preparation and uses. US Patent No. 6197349, 2000.
4. Muller RH, Ruge SA. Solid lipid nanoparticles (SLN) for controlled drug delivery. In: Submicron emulsions in drug targeting and delivery. Amsterdam: Harwood Academic Publishers, 1998. p. 219-34.
5. Gulati M., Grover M., Singh S., Singh M. Lipophilic drug derivatives in liposomes. Int J Pharm. 165:1998;129-168.
6. Lander R., Manger W., Scouloudis M., Ku A., Davis O., Lee A. Gaulin homogenization. a mechanistic study Biotechnol Prog. 16:2000;80-85.
7. Siekmann B., Westesen K. Melt-homogenized solid lipid nanoparticles stabilized by the nontonic surfactant tyloxapol 1. Preparation and particle size determination. Pharm Pharmacol Lett. 3:1994;194-197.
8. Sjostrom B., Bergenstani B. Preparation of submicron drug particles in lecithin-stabilized o/w emulsions 1 model studies of the precipitation of cholesterylacetate. Int J Pharm. 88:1992;53-62.
9. Siekmann B., Westesen K. Investigation on solid lipid nanoparticles prepared by precipitation in o/w emulsion. Eur J Pharm Biopharm. 43:1996;104-109.
10. Speiser P. Lipid nanopellets als hagersystem fur arznermitter zur peroraten anwenonng. EP No. 016/825, 1990.
11. Domb AI. Lipospheres for controlled delivery of substances. US Patent No.188837, 1993.
12. Sarkar N.N. Mifepristone. bioavailability, pharmacokinetics and use-effectiveness Eur J Obstet Gynecol Reprod Biol. 101:2002;113-120.
13. Danino D., Talmon Y., Zana R. Vesicle-to-micelle transformation in systems containing dimeric surfactants. J Colloid Interface Sci. 185:1997;84-93.
14. Schwarz C., Mehnert W., Muller R.H. Influence of production parameters of solid lipid nanoparticles (SLN) on the suitability for intravenous injection. Eur J Pharm Biopharm. 40:1994;248-256.
15. Muller R.H., Schwarz C., Mehnert W., Lucks J.S. Production of solid lipid nanoparticles for controlled drug delivery. Proc Int Symp Control Rel Bioact Mater. 20:1993;480-487.
16. Liedtke S., Wissing S., Muller R.H., Mader K. Influence of high pressure homogenization equipment on nanodispersions characteristics. Int J Pharm. 196:2000;183-185.
17. Westesen K., Siekmann B., Koch M.H.J. Investigations on the physical state of lipid nanoparticles by synchrotron X-ray diffraction. Int J Pharm. 93:1993;189-199.
18. Muller R.H., Jacobs C., Kayser O. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev. 47:2001;3-19.
19. Muller RH, Bohm BHL. In: Muller RH, Benita S, Bohm B, editors. Emulsions and nanosuspensions for the formulation of poorly soluble drugs. Stuttgart: Medpharm Scientific, 1998. p. 149-73.
20. Liversidge G.C., Cundy K.C. Particle size reduction for improvement of oval bioavailability of hydrophobic drugs.1. Absolute oral bioavailability of nanocrystalline danazole in beagle dogs. Int J Pharm. 127:1995;91-97.
21. Liversidge G.C. Drug nanocrystals for improved drug delivery. Int Symp Control Rel Bioact Mater. 23:1996;74-81.
22. Siekmann B., Westesen K. Thermoanalysis of the recrystallization process of melt-homogenized glycerid nanoparticles. Colloids Surf B. 3(6):1994;159-175.
23. Westesen K., Bunjes H., Koch H.J. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Rel. 48:1997;189-197.
24. Jenning V., Gysler A., korting M.S., Gohla S. Vitamin A loaded solid lipid nanoparticles for topical use. occlusive properties and drug penetration into poreinc skin Eur J Pharm Biopharm. 50:2000;189-197.
25. Muller R.H., Dobrucki R., Radomska A. Solid lipid nanoparticles as a new formulation with retinal. Acta Pol Pharm-Drug Res. 56:1999;117-120.